QIAGEN powered by

Oncology

Provide oncologists with patient-specific diagnostic and prognostic reports for any alteration in any cancer type with clinical decision support software or professional interpretation services

17 million

new cancer cases diagnosed every year (1)

85%

of the global oncology market is focused 
on targeted therapies (2)

100+

new clinical trials open each month (3) 

Reduce time to interpret clinical NGS tests by 85%

Nothing about cancer is simple. With such a life-changing diagnosis, oncologists need confidence that their genetic testing labs are considering the most up-to-date, relevant data to guide their diagnostic and treatment decisions.

QIAGEN Clinical Insights (QCI) for Oncology offers software and services to empower molecular pathologists with expert-curated content to intelligently navigate the biological characteristics of genetic alterations and their clinical relevance to a patient’s tumor profile. Capable of interpreting any alteration in any cancer type, QCI for Oncology helps molecular pathologists deliver personalized, evidence-based treatment recommendations for an expanding menu of tests in a fraction of the time.

In-sourced or out-sourced?

Whether building a first-class NGS variant interpretation and reporting pipeline or looking for an experienced partner to interpret tests for you, QCI for Oncology has two trusted solutions to fit your lab’s specific needs:

“Why Precision Insights? We save time. In clinical practice, outside of academics, most people don’t have time to do the research at an adequate level and with consistency required from one case to the next. We get an 85-90% reduction in case preparation time using Precision Insights.”

Anne Berry, M.D., 
Scientific Director of Personalized Medicine and Medical Director of Molecular Diagnostics
Swedish Cancer Institute and CellNetix Pathology and Laboratories

Provide actionable cancer care insights

With the promise of precision medicine becoming a reality, molecular profiling has become standard of care for many cancer types. More than ever, oncologists need a trusted profiling partner to provide reliable, high-quality molecular information to guide more precise and individualized treatment decisions.

QCI for Oncology enables standardized reporting according to AMP/ASCO/CAP guidelines for the interpretation and reporting of somatic variants (4) and provides biological insights based on ACMG guidelines (5).

To ensure consistency and reproducibility of results, QCI for Oncology provides full transparency to review the criteria and evidence supporting each classification and gives you real-time visibility into active clinical trial registries and available FDA-approved therapeutics. 

Clinical oncology testing solutions

QCI Interpret

For molecular diagnostic labs performing variant interpretation and reporting in-house, QCI Interpret enables faster test turnaround times and higher confidence reporting for any assay on your sequencing platform.

Learn more >

QCI Precision Insights

For molecular diagnostic labs outsourcing somatic variant interpretation, QCI Precision Insights, powered by N-of-One, offers rapid turnaround times and customized variant-level interpretation for patient-specific reports.

Learn more >

Clinical Testing Services

From pipeline development to secondary analysis and variant curation, QIAGEN Clinical Testing Services offers customized end-to-end clinical reporting solutions to fast-track your lab’s scalability and profitability goals.

Learn more >

Interpreting NGS cancer panels?

Whether new to NGS or an experienced user, learn how QCI for Oncology can increase your lab’s efficiency, confidence, and test menu offerings. 

Speak with a clinical testing expert today.

Hereditary Diseases

Empower clinicians and their patients to make critical and timely healthcare decisions with the latest publications and clinical evidence

QIAGEN Clinical Insights

Deliver patient-specific reports for any NGS panel in minutes with on-demand, expert-curated content and professional interpretation services

Clinical Analysis and Interpretation Services

Leverage the benefits of automation and expert support to improve test turnaround times and clinical reporting capabilities

1. Worldwide cancer statistics. (2019, August 22). Retrieved December 15, 2019, from https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer.
2. Long, G. (2017). The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development.  The Analysis Group, Inc. Retrieved December 15, 2019, from https://www.analysisgroup.com/uploadedfiles/content/insights/publishing/the_biopharmaceutical_pipeline_report_2017.pdf
3. Curioni-Fontecedro, A. (2017). A new era of oncology through artificial intelligence. ESMO Open2(2). Retrieved December 15, 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519782/
4. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. (2017). Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 19:4–23. doi: 10.1016/j.jmoldx.2016.10.002.
5. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17:405–424. doi: 10.1038/gim.2015.30.
QIAGEN Clinical Insight (QCI) is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and clinical trials. Based on this evaluation, the software proposes a classification to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accreditations requirements.